tradingkey.logo

AstraZeneca Says Baxdrostat Met Primary And Secondary Endpoints In Phase III Trial

ReutersJul 14, 2025 6:26 AM

- AstraZeneca PLC AZN.L:

  • BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL

  • ASTRAZENECA PLC - BAXDROSTAT MEETS PRIMARY AND SECONDARY ENDPOINTS IN PHASE III TRIAL

  • ASTRAZENECA PLC - BAXDROSTAT SHOWS SIGNIFICANT REDUCTION IN SYSTOLIC BLOOD PRESSURE

  • ASTRAZENECA PLC - BAXDROSTAT AT 2MG AND 1MG DOSES REDUCES BLOOD PRESSURE

  • ASTRAZENECA: BAXDROSTAT WAS GENERALLY WELL TOLERATED WITH A FAVOURABLE SAFETY PROFILE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI